Bernstein initiated coverage of Revolution Medicines (NasdaqGS:RVMD) on May 22, 2026 with a Market Perform rating. The article highlights an analyst price forecast implying 19.64% upside, but the stance remains neutral overall. This is notable analyst coverage for the biotech name, though not a high-conviction catalyst.
Bernstein initiated coverage of Revolution Medicines (NasdaqGS:RVMD) on May 22, 2026 with a Market Perform rating. The article highlights an analyst price forecast implying 19.64% upside, but the stance remains neutral overall. This is notable analyst coverage for the biotech name, though not a high-conviction catalyst.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.15
Ticker Sentiment
